Background Issues with laboratory measurement of dabigatran include: 1. Do coagulation
assays reflect dabigatran plasma concentrations? 2. Do samples from patients treated with …

Background Knowledge of anticoagulation status during dabigatran therapy may be
desirable in certain clinical situations. Objective To determine the coagulation tests that are …

Background Dabigatran is an oral direct thrombin inhibitor for which routine laboratory
monitoring is currently not recommended. However, there are situations in which …

Background: Assessing the anticoagulant effect of dabigatran may be useful in certain
clinical settings. When plasma sampling is not available, serum or urine samples may …

Objectives: To study dabigatran etexilate, a new oral anticoagulant that functions as a direct
thrombin inhibitor. Methods: This study evaluates four methods, one of which is performed in …

Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may
be required in specific situations to prevent the risk of bleedings or thrombosis. The aim of …

INTRODUCTION: The new oral anticoagulants are effective alternatives for warfarin but
specific antidotes are not yet available for these agents to manage life-threatening bleeding …

Background Direct oral anticoagulant dabigatran was first introduced as a fixed-dose drug
without routine coagulation monitoring, but current recommendations suggest that diluted …

Objectives Dabigatran etexilate is widely used for stroke prevention in the patients with atrial
fibrillation. The anticoagulation activity of dabigatran is not necessary monitored in routine …

The oral direct thrombin inhibitor dabigatran effectively prevents arterial and venous
thromboembolism using fixed doses without the need for adjustment according to laboratory …